tiprankstipranks
Trending News
More News >
Lipella Pharmaceuticals, Inc. (LIPO)
OTHER OTC:LIPO
US Market
Advertisement

Lipella Pharmaceuticals, Inc. (LIPO) Price & Analysis

Compare
109 Followers

LIPO Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Clinical Trial ProgressLipella announced positive results from its P2a study of LP-310 in oral lichen planus (OLP), highlighting data from the first cohort which received the lowest treatment dose of 0.25mg.
Regulatory ApprovalFDA granted approval for an expanded access program (EAP) for LP-310, its oral rinse formulation of tacrolimus, for the treatment of oral lichen planus (OLP).
Bears Say
Financial NeedsThe company will likely need to raise additional capital to fund its ongoing programs.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

29.72%0.19%0.30%69.79%
29.72% Insiders
0.30% Other Institutional Investors
69.79% Public Companies and Individual Investors

LIPO FAQ

What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?
Lipella Pharmaceuticals, Inc. lowest stock price was $0.62 and its highest was $12.00 in the past 12 months.
    What is Lipella Pharmaceuticals, Inc.’s market cap?
    Lipella Pharmaceuticals, Inc.’s market cap is $3.13M.
      When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?
      Currently, no data Available
      Is Lipella Pharmaceuticals, Inc. overvalued?
      According to Wall Street analysts Lipella Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Lipella Pharmaceuticals, Inc. pay dividends?
        Lipella Pharmaceuticals, Inc. does not currently pay dividends.
        What is Lipella Pharmaceuticals, Inc.’s EPS estimate?
        Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Lipella Pharmaceuticals, Inc. have?
        Lipella Pharmaceuticals, Inc. has 4,467,395 shares outstanding.
          What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?
          Currently, no hedge funds are holding shares in LIPO

          Company Description

          Lipella Pharmaceuticals, Inc.

          Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
          Similar Stocks
          Company
          Price & Change
          Follow
          Palatin Technologies
          MetaVia
          Aptorum Group
          TransCode Therapeutics
          Conduit Pharmaceuticals
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis